Jocasta Neuroscience is a preclinical-stage biotech advancing a proprietary formulation of the longevity protein a-Klotho (lead asset JN-0413) to treat cognitive impairment linked to neurodegenerative disease. The company’s a-Klotho program has shown robust cognition enhancement across multiple species, 11 cognitive tasks, and at five institutions. Jocasta holds exclusive IP and is positioned as the leading company with an active a-Klotho program; the underlying technology was developed at UCSF by Dr. Dena Dubal. Management includes CEO Dr. Albert Agro and cofounders Dr. Dena Dubal and Michael Davidson, who remain closely involved in scientific and strategic direction. The company plans to advance JN-0413 into clinical development, with IND submission targeted for Q4 2026 and clinical trials planned to begin within the next 18 months. The Series A financing will fund progression through Phase 1 (single ascending dose and multiple ascending dose studies).

Total raised

$35M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2025